AU2009223649B2 - Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection - Google Patents

Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection Download PDF

Info

Publication number
AU2009223649B2
AU2009223649B2 AU2009223649A AU2009223649A AU2009223649B2 AU 2009223649 B2 AU2009223649 B2 AU 2009223649B2 AU 2009223649 A AU2009223649 A AU 2009223649A AU 2009223649 A AU2009223649 A AU 2009223649A AU 2009223649 B2 AU2009223649 B2 AU 2009223649B2
Authority
AU
Australia
Prior art keywords
suspension composition
chloride
suspension
compositions
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009223649A
Other languages
English (en)
Other versions
AU2009223649A1 (en
Inventor
Bhagwati P. Kabra
Ruma Sarkar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2009223649A1 publication Critical patent/AU2009223649A1/en
Application granted granted Critical
Publication of AU2009223649B2 publication Critical patent/AU2009223649B2/en
Assigned to ALCON INC. reassignment ALCON INC. Request for Assignment Assignors: ALCON RESEARCH, LTD.
Assigned to NOVARTIS AG reassignment NOVARTIS AG Request for Assignment Assignors: ALCON INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2009223649A 2008-03-11 2009-03-10 Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection Active AU2009223649B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3545908P 2008-03-11 2008-03-11
US61/035,459 2008-03-11
PCT/US2009/036652 WO2009114521A1 (en) 2008-03-11 2009-03-10 Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection

Publications (2)

Publication Number Publication Date
AU2009223649A1 AU2009223649A1 (en) 2009-09-17
AU2009223649B2 true AU2009223649B2 (en) 2013-08-29

Family

ID=40548758

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009223649A Active AU2009223649B2 (en) 2008-03-11 2009-03-10 Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection

Country Status (21)

Country Link
US (3) US8128960B2 (enExample)
EP (1) EP2262506B1 (enExample)
JP (1) JP5581227B2 (enExample)
KR (1) KR101555293B1 (enExample)
CN (1) CN101959519B (enExample)
AR (1) AR070824A1 (enExample)
AU (1) AU2009223649B2 (enExample)
BR (1) BRPI0909630B8 (enExample)
CA (1) CA2717605C (enExample)
CL (1) CL2009000573A1 (enExample)
DK (1) DK2262506T3 (enExample)
ES (1) ES2471122T3 (enExample)
MX (1) MX2010009974A (enExample)
PL (1) PL2262506T3 (enExample)
PT (1) PT2262506E (enExample)
RU (1) RU2481842C2 (enExample)
SI (1) SI2262506T1 (enExample)
TW (1) TWI468165B (enExample)
UY (1) UY31699A1 (enExample)
WO (1) WO2009114521A1 (enExample)
ZA (1) ZA201005839B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
RU2481842C2 (ru) * 2008-03-11 2013-05-20 Алькон Рисерч, Лтд. Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций
KR20110099044A (ko) * 2008-12-22 2011-09-05 알콘 리서치, 리미티드 후안부에 유효농도의 활성제를 전달하기 위한 국소 안용액 조성물
WO2012051575A2 (en) 2010-10-15 2012-04-19 Iscience Interventional Corporation Device for ocular access
CN102008488B (zh) * 2010-11-24 2012-10-10 广州固志医药科技有限公司 一种曲安奈德眼用制剂及其制备方法
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
AU2013342275B2 (en) * 2012-11-08 2017-11-09 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
SG10201702674PA (en) 2013-05-03 2017-06-29 Clearside Biomedical Inc Apparatus and methods for ocular injection
WO2014197317A1 (en) 2013-06-03 2014-12-11 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
WO2015196085A2 (en) 2014-06-20 2015-12-23 Clearside Biomedical, Inc. Variable diameter cannula and methods for controlling insertion depth for medicament delivery
US9694145B1 (en) 2016-03-29 2017-07-04 Joseph Onorato Auto-injector systems and method for delivering cyst medication on demand
JP2019514581A (ja) 2016-05-02 2019-06-06 クリアサイド バイオメディカル，インコーポレイテッド 眼の薬物送達のためのシステムおよび方法
US10973681B2 (en) 2016-08-12 2021-04-13 Clearside Biomedical, Inc. Devices and methods for adjusting the insertion depth of a needle for medicament delivery
WO2018204515A1 (en) 2017-05-02 2018-11-08 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
WO2019136512A1 (en) * 2018-01-10 2019-07-18 Eye Co Pty Ltd Medical device and pharmaceutical composition for treatment of an eye disease or condition
USD893715S1 (en) 2018-11-06 2020-08-18 Joseph Onorato Measurement guide for a cyst, lesion or skin disorder
CA3136814A1 (en) * 2019-04-16 2020-10-22 Clearside Biomedical, Inc. Injectable triamcinolone formulations
US10814001B1 (en) 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
CN114010593A (zh) * 2021-11-23 2022-02-08 莱默(北京)药业科技有限公司 一种曲安奈德混悬注射液及制备方法
CN115969784B (zh) * 2022-12-26 2025-10-21 昆明积大制药股份有限公司 曲安奈德注射液的制备方法
WO2025114562A1 (en) * 2023-11-30 2025-06-05 Institut National de la Santé et de la Recherche Médicale Intravitreal spironolactone suspension

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1867334A1 (en) * 2005-02-18 2007-12-19 Santen Pharmaceutical Co., Ltd. Method of relieving or avoiding side effect of steroid compound

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962430A (en) * 1974-08-07 1976-06-08 Merck & Co., Inc. Sterilization of solid non-electrolyte medicinal agents employing sodium chloride
US4370325A (en) * 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US4432964A (en) * 1981-08-24 1984-02-21 Alza Corporation Topical composition containing steroid in two forms released independently from polymeric carrier
US5164190A (en) * 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
WO1995003807A1 (en) 1993-07-27 1995-02-09 The University Of Sydney Treatment of age-related macular degeneration
AU4472396A (en) 1994-12-30 1996-07-24 American Home Products Corporation Clear non-alcoholic hydrocortisone solutions
CA2336703A1 (en) 1998-07-10 2000-01-20 The University Of Sydney Prophylactic treatments of neovascularisation in macular degeneration
AR026073A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
AUPQ496500A0 (en) 2000-01-06 2000-02-03 University Of Sydney, The Kit
US6395294B1 (en) 2000-01-13 2002-05-28 Gholam A. Peyman Method of visualization of the vitreous during vitrectomy
US6656505B2 (en) * 2000-07-21 2003-12-02 Alpharma Uspd Inc. Method for forming an aqueous flocculated suspension
JP5000835B2 (ja) * 2000-08-25 2012-08-15 千寿製薬株式会社 水性懸濁液剤
DE60233414D1 (de) * 2001-07-09 2009-10-01 Combinatorx Inc Kombinationen für die behandlung entzündlicher erkrankungen
US20030129242A1 (en) 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
RU2005129276A (ru) * 2003-02-20 2006-01-27 Алькон, Инк. (Ch) Применение стероидов для лечения субъектов, страдающих заболеванием глаз
US20040186084A1 (en) 2003-03-21 2004-09-23 Akorn, Inc. Triamcinolone formulations and methods for their preparation and use
CA2539023A1 (en) * 2003-09-23 2005-04-14 Alcon Inc. Triamcinolone acetonide and anecortave acetate formulations for injection
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20060141049A1 (en) 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
JP2007516297A (ja) * 2003-12-23 2007-06-21 アルザ・コーポレーシヨン 制御送達用薬剤組成物の溶解度を高くする方法および投薬形態物
EP1706095B1 (en) 2004-01-20 2008-12-24 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20070225727A1 (en) 2004-05-31 2007-09-27 Keiichi Matsuhisa Transparent Tissue-Visualizng Preparation
US20060089590A1 (en) 2004-10-27 2006-04-27 John Higuchi Methods and devices for sustained in-vivo release of an active agent
US20080008762A1 (en) 2004-11-17 2008-01-10 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Steroid Formulation And Methods Of Treatment Using Same
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
ITRM20050547A1 (it) 2005-11-04 2007-05-05 Sooft Italia S R L Gel oftalmico composto da triamcinolone acetonide e da un polimero poliacrilico.
RU2481842C2 (ru) * 2008-03-11 2013-05-20 Алькон Рисерч, Лтд. Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1867334A1 (en) * 2005-02-18 2007-12-19 Santen Pharmaceutical Co., Ltd. Method of relieving or avoiding side effect of steroid compound

Also Published As

Publication number Publication date
US8128960B2 (en) 2012-03-06
CN101959519B (zh) 2013-03-20
CN101959519A (zh) 2011-01-26
PT2262506E (pt) 2014-06-24
US20120115829A1 (en) 2012-05-10
KR20100127267A (ko) 2010-12-03
HK1146464A1 (en) 2011-06-10
EP2262506B1 (en) 2014-05-07
BRPI0909630B8 (pt) 2021-05-25
CL2009000573A1 (es) 2010-01-04
US20120116216A1 (en) 2012-05-10
TWI468165B (zh) 2015-01-11
KR101555293B1 (ko) 2015-10-06
US8211880B2 (en) 2012-07-03
BRPI0909630B1 (pt) 2019-03-26
JP5581227B2 (ja) 2014-08-27
US20090233890A1 (en) 2009-09-17
ZA201005839B (en) 2011-10-26
CA2717605C (en) 2012-05-15
JP2011513492A (ja) 2011-04-28
EP2262506A1 (en) 2010-12-22
CA2717605A1 (en) 2009-09-17
AU2009223649A1 (en) 2009-09-17
WO2009114521A1 (en) 2009-09-17
MX2010009974A (es) 2010-09-30
SI2262506T1 (sl) 2014-07-31
DK2262506T3 (da) 2014-06-10
TW200940071A (en) 2009-10-01
BRPI0909630A2 (pt) 2015-09-22
RU2010141542A (ru) 2012-04-20
PL2262506T3 (pl) 2014-09-30
UY31699A1 (es) 2009-05-29
RU2481842C2 (ru) 2013-05-20
ES2471122T3 (es) 2014-06-25
AR070824A1 (es) 2010-05-05

Similar Documents

Publication Publication Date Title
US8128960B2 (en) Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
EP3843704B1 (en) Emulsion formulations of multikinase inhibitors
US9089478B2 (en) Peripherally administered viscous formulations
Madan et al. In situ forming polymeric drug delivery systems
KR102055937B1 (ko) 불용성 코르티코스테로이드 및 수용성 코르티코스테로이드를 포함하는 약학적 제형
US20050065137A1 (en) Triamcinolone acetonide and anecortave acetate formulations for injection
TWI674899B (zh) 醫藥配方
JPH01287041A (ja) 徐放性製剤
HK1146464B (en) Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ALCON INC.

Free format text: FORMER OWNER(S): ALCON RESEARCH, LTD.

PC Assignment registered

Owner name: NOVARTIS AG

Free format text: FORMER OWNER(S): ALCON INC.